Key result
The oral PCSK9 inhibitor enlicitide showed a marked reduction from baseline in low-density lipoprotein cholesterol levels compared with placebo.
Why the study?
Does the oral PCSK9 inhibitor enlicitide reduce LDL cholesterol compared with placebo?
Does the oral PCSK9 inhibitor enlicitide reduce LDL cholesterol compared with placebo?
This letter highlights that while enlicitide reduces LDL cholesterol, its long-term cardiovascular benefits and durability remain unproven.
To the Editor: The CORALreef Lipids trial, conducted by Navar et al. (Feb. 5 issue), 1 showed a marked reduction from baseline in the low-density lipoprotein (LDL) cholesterol level with the oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor enlicitide, as compared with placebo. We would like to note some limitations that warrant attention. First, the trial evaluated only surrogate lipid end points without evaluating cardiovascular end points, 2 and the 52-week follow-up cannot confirm the long-term efficacy of treatment, durability of effect, or potential resistance to the drug, which may occur with compensatory PCSK9 up-regulation. The answers to these questions will . . .
No takes yet. Share an insight, caveat, or question.
A 2026 study reported a letter. enlicitide vs. placebo was evaluated on low-density lipoprotein (LDL) cholesterol level. The oral PCSK9 inhibitor enlicitide showed a marked reduction from baseline in low-density lipoprotein cholesterol levels compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: